PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Cash & equivalents declining -26.68% while RVPH's grows 0.00%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Below half of RVPH's -99.68%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Higher Other Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-27.05%
Below half of RVPH's -99.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.44%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-5.69%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Below half of RVPH's 0.94%. Michael Burry sees a potential red flag for stagnation or capital shortage.
9.15%
Higher Accounts Payable Growth compared to RVPH's zero value, indicating worse performance.
-74.86%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Higher Total Current Liabilities Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Higher Total Non-Current Liabilities Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Higher Total Liabilities Growth compared to RVPH's zero value, indicating worse performance.
1.65%
Higher Common Stock (Book Value) Growth compared to RVPH's zero value, indicating worse performance.
-3.34%
Both RVPH and the company show zero Retained Earnings Growth.
-6.51%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
Both RVPH and the company show zero Total Stockholders' Equity Growth.
-25.21%
Below half RVPH's -88.96%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Similar yoy to RVPH's -100.00%. Walter Schloss notes parallel moves in the investment portfolio.
-11.75%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
27.85%
Higher Net Debt Growth compared to RVPH's zero value, indicating worse performance.